Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Azafaros concludes Phase III trial recruitment for GM1/GM2 gangliosidoses
2+ day, 5+ hour ago (323+ words) The study enrolled at least 75 patients across 25 clinical sites in 13 countries. A part of the company’s NAVIGATE programme, the trial aims to assess the effects of nizubaglustat, an orally administered small molecule, on neurological manifestations and disease progression in these…...
Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013
2+ day, 7+ hour ago (294+ words) The Phase I trial aims to determine maximum tolerated dose, evaluate pharmacokinetics, and gather preliminary efficacy data. Bio-Thera Solutions has initiated dosing in a Phase I clinical trial of BAT8013, an antibody drug conjugate (ADC) designed to target cluster of differentiation…...
China's rapid rise in drug development casts a long shadow over US oncology
2+ day, 1+ hour ago (323+ words) China’s rapid rise in drug development casts a long shadow over US oncology Clinical Trials Arena 2026 marks a clear turning point for China’s position in the global clinical trials arena, particularly in oncology. At this year’s American Society of Clinical…...
Study deems it safe to switch children with pneumonia to oral antibiotics
2+ day, 3+ hour ago (376+ words) The study enrolled 1,101 children with pneumonia who were randomised to receive either oral or injectable antibiotics after an injectable run-in. Children hospitalised with severe pneumonia can safely switch from injectable to oral antibiotics once they begin to recover, a clinical…...
Operation Trialblazer: Expedited IND delivers a strategic edge in dynamic global landscape
2+ day, 8+ hour ago (1366+ words) Operation Trialblazer is expected to shape early-stage planning, but experts debate its long term impact. With Operation Trialblazer set to expedite early-stage research in the US, experts anticipate that the fast-tracked investigational new drug (IND) stage could be a significant…...
J&J’s multiple myeloma combo cuts risk of death by 62% in Phase III study
2+ day, 6+ hour ago (519+ words) The MonumenTAL-6 results add to the growing body of evidence touting Talvey and Tecvayli’s use in earlier multiple myeloma treatment lines. Johnson & Johnson (J&J) has posted a duo of Phase III wins for two of its budding multiple myeloma combination…...
Ribo reports vortosiran Phase IIa trial results for coronary artery disease
3+ day, 4+ hour ago (286+ words) Patients completing the high-dose cohort achieved a 92% average reduction in FXI activity for several months. Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals, collectively known as Ribo, has reported initial results from its Phase IIa clinical trial of vortosiran (RBD4059) in…...
Another win for Lilly’s triple-g agonist in two more Phase III trials
3+ day, 2+ hour ago (667+ words) If approved, Lilly’s triple-g agonist would become the company’s fifth glucagon-based drug to be marketed. Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded in type 2 diabetes and obesity....
Crystalys banks $130m to progress gout drug, plan for commercial readiness
3+ day, 7+ hour ago (420+ words) The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for dotinurad. Crystalys Therapeutics has secured $130m in a Series B raise to push its gout therapy, dotinurad, further down the pipeline, while gearing the drug up for…...
Celldex’s mAb fails to show benefit in Phase II prurigo nodularis trial
4+ day, 5+ hour ago (168+ words) Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including…...